TY - JOUR
T1 - Polymeric nanomedicine for cancer therapy
AU - Park, Jae Hyung
AU - Lee, Seulki
AU - Kim, Jong Ho
AU - Park, Kyeongsoon
AU - Kim, Kwangmeyung
AU - Kwon, Ick Chan
N1 - Funding Information:
This research was supported by the KIST intramural “Molecular Imaging Research Project” and by a Grant from the Korea Health 21 R&D Project, Ministry of Health & Welfare, Republic of Korea (A062254B8150506N11C011B).
Copyright:
Copyright 2008 Elsevier B.V., All rights reserved.
PY - 2008/1
Y1 - 2008/1
N2 - Nanomedicine, an offshoot of nanotechnology, refers to highly specific, molecular-scale medical intervention for treating disease or repairing damaged tissues. In recent years, polymer-based nanomedicine, a field that includes the use of polymer-DNA complexes (polyplexes), polymer-drug conjugates, and polymer micelles bearing hydrophobic drugs, has received increasing attention for its ability to improve the efficacy of cancer therapeutics. Owing to their small size and excellent biocompatibility, nanosized polymer therapeutic agents can circulate in the bloodstream for long periods of time, allowing them to reach the target site. In addition, chemical modification of polymer therapeutic agents with ligands capable of specifically binding receptors that are over-expressed in cancer cells can markedly augment therapeutic efficiency. This review highlights the characteristics of cancer that provide nanodrug targeting opportunities and discusses rational approaches for future development of polymeric nanomedicines.
AB - Nanomedicine, an offshoot of nanotechnology, refers to highly specific, molecular-scale medical intervention for treating disease or repairing damaged tissues. In recent years, polymer-based nanomedicine, a field that includes the use of polymer-DNA complexes (polyplexes), polymer-drug conjugates, and polymer micelles bearing hydrophobic drugs, has received increasing attention for its ability to improve the efficacy of cancer therapeutics. Owing to their small size and excellent biocompatibility, nanosized polymer therapeutic agents can circulate in the bloodstream for long periods of time, allowing them to reach the target site. In addition, chemical modification of polymer therapeutic agents with ligands capable of specifically binding receptors that are over-expressed in cancer cells can markedly augment therapeutic efficiency. This review highlights the characteristics of cancer that provide nanodrug targeting opportunities and discusses rational approaches for future development of polymeric nanomedicines.
KW - Angiogenesis
KW - Cancer therapy
KW - Drug carrier
KW - Polymeric nanomedicine
KW - Targeted delivery
UR - http://www.scopus.com/inward/record.url?scp=37249068568&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=37249068568&partnerID=8YFLogxK
U2 - 10.1016/j.progpolymsci.2007.09.003
DO - 10.1016/j.progpolymsci.2007.09.003
M3 - Review article
AN - SCOPUS:37249068568
SN - 0079-6700
VL - 33
SP - 113
EP - 137
JO - Progress in Polymer Science
JF - Progress in Polymer Science
IS - 1
ER -
